Liver Disease And Pharmacotherapy For Alcoholism | 71907
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Liver disease and pharmacotherapy for alcoholism

12th Euro-Global Gastroenterology Conference

Mike McDonough

Western Hospital, Australia

ScientificTracks Abstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X-C1-052

A common clinical question to Addiction specialists concerns whether a medication to treat a patient’s alcoholism should be used and if so, when could such be commenced given the patient has liver disease. Alcohol consumption itself is a principal driver of alcoholic liver disease and as such, should prompt treatment intervention. While there is a reasonable evidence for medications that treat alcoholism, very little evidence exists to guide the decision to use such medication in the presence of clinically significant liver disease. This presentation reviews recent literature on pharmacotherapy for alcohol dependence relating particularly to patients having comorbid liver disease and alcoholism. It concludes with an outline for a Risk versus Benefit approach to pharmacotherapy decision-making.

Mike McDonough an Associate Professor worked for the University of Melbourne in the department of Medicine & Radiology. Now he is working as Medical Director- Drug health services in Western Health.